Quick Order

PLA2G1B Antibody, Rabbit PAb, Antigen Affinity Purified

    DatasheetReviewsRelated ProductsProtocols
    Mouse PLA2G1B Antibody Product Information
    Immunogen:Recombinant Mouse PLA2G1B protein (Catalog#50329-M08H)
    Clone ID:
    Ig Type:Rabbit IgG
    Concentration:
    Formulation:0.2 μm filtered solution in PBS with 5% trehalose
    Preparation:Produced in rabbits immunized with purified, recombinant Mouse PLA2G1B (rM PLA2G1B; Catalog#50329-M08H; NP_035237.1; Met 1-Cys146). PLA2G1B specific IgG was purified by Mouse PLA2G1B affinity chromatography.
    Other PLA2G1B Antibody Products

    Anti-Histone H3 rabbit monoclonal antibody at 1:200 dilution

    Lane A: NIH3T3 Whole Cell Lysate

    Lane B: Hela Whole Cell Lysate

    Lysates/proteins at 30 μg per lane.

    Secondary

    Goat Anti-Rabbit IgG (H+L)/HRP at 1/10000 dilution.

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size:15 kDa

    Observed band size:17 kDa

    PLA2G1B Background

    phospholipase A2, also known as Phosphatidylcholine 2-acylhydrolase 1B, Group IB phospholipase A2, PLA2 and PLA2G1B, is a secreted protein which belongs to the phospholipase A2 family. Phospholipase A2 / PLA2G1B catalyzes the release of fatty acids from glycero-3-phosphocholines. The best known varieties are the digestive enzymes secreted as zymogens by the pancreas of mammals. Sequences of pancreatic Phospholipase A2 / PLA2G1B enzymes from a variety of mammals have been reported. One striking feature of these enzymes is their close homology to venom phospholipases of snakes. Other forms of Phospholipase A2 / PLA2G1B have been isolated from brain, liver, lung, spleen, intestine, macrophages, leukocytes, erythrocytes, inflammatory exudates, chondrocytes, and platelets. Mice lacking in Phospholipase A2 / PLA2G1B are resistant to obesity and diabetes induced by feeding a diabetogenic high-fat/high-carbohydrate diet. Oral supplementation of a diabetogenic diet with the PLA2G1B inhibitor methyl indoxam effectively suppresses diet-induced obesity and diabetes. PLA2G1B inhibition may be a potentially effective oral therapeutic option for treatment of obesity and diabetes.

    Mouse PLA2G1B References
  • Labonté,E.D. et al., 2006, Diabetes. 55 (4) :935-41.
  • Mounier,C.M. et al.,2008, Br J Cancer. 98 (3):587-95.
  • Hui,D.Y. et al., 2009, Br J Pharmacol. 157 (7):1263-9.
  • Labonté,E.D. et al., 2010, FASEB J. 24 (7):2516-24.
  • Product nameProduct name
    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"